What is the maximum daily dose of mirtazapine for adults?

Maximum Daily Dose of Mirtazapine

The maximum daily dose of mirtazapine for adults is 45 mg per day, administered as a single dose preferably in the evening prior to sleep. 1

Dosing Guidelines

Standard Dosing Regimen

• Starting dose: 15 mg once daily in the evening 1
• Dose titration: If inadequate response to 15 mg, increase up to the maximum of 45 mg per day 1
• Timing of dose changes: Do not adjust doses more frequently than every 1-2 weeks to allow adequate time to evaluate response 1

Pharmacokinetic Rationale

• Mirtazapine demonstrates linear pharmacokinetics over the dose range of 15-80 mg, though the FDA-approved maximum remains 45 mg 1
• The elimination half-life of 20-40 hours supports once-daily dosing 1, 2
• Steady-state plasma levels are achieved within 5 days, with approximately 50% drug accumulation 1

Clinical Trial Evidence

Effective Dose Range in Studies

• Clinical trials establishing efficacy used doses ranging from 5-35 mg/day, with mean doses for completers ranging from 21-32 mg/day 1
• The therapeutic dosage range of 15-45 mg/day has been validated across multiple placebo-controlled trials 3
• Higher doses (up to 80 mg/day) have been studied pharmacokinetically but are not FDA-approved 4, 2

Important Dosing Modifications

Drug Interactions Requiring Adjustment

• Strong CYP3A inducers (carbamazepine, phenytoin, rifampin): May need to increase mirtazapine dose; conversely, decrease dose if inducer is discontinued 1
• Strong CYP3A inhibitors (ketoconazole, clarithromycin): May need to decrease mirtazapine dose 1
• Cimetidine: May require dose reduction of mirtazapine 1

Special Populations

• Elderly patients: Oral clearance reduced by 40% in elderly males and 10% in elderly females compared to younger patients; females exhibit significantly longer elimination half-lives (37 hours vs 26 hours in males) 1
• Renal impairment: Clearance reduced by approximately 30% with GFR 11-39 mL/min/1.73 m² and 50% with GFR <10 mL/min/1.73 m² 1
• Hepatic impairment: Oral clearance decreased by approximately 30% 1

Critical Safety Considerations

Discontinuation

• Gradual taper required: Reduce dosage gradually rather than stopping abruptly to minimize withdrawal symptoms 1

Pre-Treatment Screening

• Screen all patients for personal or family history of bipolar disorder, mania, or hypomania before initiating treatment 1

MAOI Interactions

• Allow at least 14 days between discontinuing an MAOI and starting mirtazapine 1
• Allow at least 14 days after stopping mirtazapine before starting an MAOI 1

Common Pitfalls

Sedation paradox: Increased sedation is actually more common at subtherapeutic doses; using appropriate doses (≥15 mg from treatment initiation) substantially reduces sedation complaints 4

Overdose safety: Mirtazapine has demonstrated safety in overdose, with cases up to 975 mg causing only significant sedation without cardiovascular, respiratory effects, or seizures 3